Cure candidates: Characteristics of >10yr progression-free survivors (PFS-10) and continuous CR (CCR-10) after total therapy 1 and 2 (TT1, TT2) for multiple myeloma (MM).
Sarah Waheed
No relevant relationships to disclose
Frits Van Rhee
No relevant relationships to disclose
Adam Rosenthal
No relevant relationships to disclose
Saad Zafar Usmani
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Millennium; Onyx
Mian Adnan Waheed
No relevant relationships to disclose
Antje Hoering
No relevant relationships to disclose
Bart Barlogie
Consultant or Advisory Role - Celgene; Millennium
Research Funding - Celgene; Millennium